The data will be presented as Syncromune continues to advance the ongoing, multicenter, Phase 2a LEGION-100 trial (NCT06533644), which is evaluating SYNC-T Therapy SV-102 in patients with metastatic ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...

Researchers have created the first stable prostate cancer cell lines resistant to blood-flow-level shear stress and identified the calcium-buffering gene CALB2 as a key driver of their survival.

Direct comparative and network meta analysis of PARP inhibitor and androgen receptor targeted therapies in first line mCRPC: Defining the optimal regimen among 8,997 patients. All groups compare ...

Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than ...

In patients with oligometastatic prostate cancer, metastasis-directed therapy plus standard of care was associated with significant improvements in progression-free survival (PFS), radiographic PFS, ...

"The number of men living with prostate cancer also continues to rise, so it's vital that we see investment in prostate ...

A new study indicated that the Bellmunt Risk Score can help stratify survival outcomes in patients with metastatic castration-resistant prostate cancer. Using data from more than 1700 patients across ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ...

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...

PSA score at 24 weeks was the strongest predictor of survival, with a PSA concentration of 0.2 ng/mL or less predicting favorable outcomes in this group. Serum prostate-specific antigen (PSA) scores ...